Healthcare technology continues to evolve as supply chains catch up to other industries. With that, new opportunities exist for greater efficiency, better forecasting, more accountability and end-to-end visibility. Still, barriers to operationalizing these capabilities remain.
Justifying ROI on essential tech investments in digital healthcare
Many pharmaceutical and medical device manufacturers continue to struggle with interoperability, which is the transfer and use of data between computer systems and software. Serialization, the process of converting software into a series of bytes for easier storage, is also a challenge. Further, internal supply chain teams must prove or realize their return on investment (ROI) to justify essential technology investments in digital healthcare.
These issues become especially challenging as manufacturers finalize preparations for the 2023 Drug Supply Chain Security Act (DSCSA) requirements, which call for the serialization and tracking of individual healthcare products. According to Healthcare Packaging, “Some difficult and costly requirements are behind us, but the most complex requirements are coming in the near future.”1
This guide identifies opportunities for medical and pharmaceutical manufacturers to achieve a future state for their supply chains, including end-to-end visibility, better forecasting and easier compliance with oncoming industry regulations.
What you’ll learn in our report:
- How medical manufacturers are taking big steps toward supply chain digitization and visibility.
- Why most medical manufacturers are almost prepared for compliance with the DSCSA.
- Why 28% of medical manufacturers place importance on real-time shipping controls.
- And, finally, how to create a flexible supply chain that adapts in real time.
